TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: 4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects must be able to understand and communicate with the investigator and comply with the requirements of the study and must give a written, signed and dated informed consent before any study related activity is performed. Where relevant, a legal representative will also sign the informed consent according to local laws and regulations.~2. Subjects who complete Week 52 of study CAIN457A2304 or complete Week 40 of study CAIN457A2307~3. Subjects expected to benefit from participation in the extension study, as assessed by the subject and investigator~Exclusion Criteria:~1. A protocol deviation in the core studies which according to the investigator will prevent the meaningful analysis of the extension study for the individual subject~2. Ongoing use of prohibited psoriasis or non-psoriasis treatments. Time period from last use of prohibited treatments in the core study to first dose of study drug in this extension study.~3. Subjects expected to be exposed to an undue safety risk if participating in the trial~4. Current severe progressive or uncontrolled disease which in the judgment of the investigator renders the subject unsuitable for the trial~5. Plans for administration of live vaccines during the study period~6. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (\>10 mIU/mL).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AIN457 150 mg - Fixed Interval (FI) (Type: EXPERIMENTAL): 1 s.c. Secukinumab 150 mg Pre-filled seringue (PFS) injection + 1 s.c. Placebo (PBO) Secukinumab PFS injection every 4 weeks
- AIN457 150 mg - Start of relapse (SoR) (Type: EXPERIMENTAL): Start of relapse: 1 s.c. Secukinumab 150 mg PFS injection + 1 s.c. PBO Secukinumab PFS injection every 4 weeks~Otherwise: 2 s.c. PBO Secukinumab PFS injections every 4 weeks
- AIN457 300 mg - Fixed Interval (FI) (Type: EXPERIMENTAL): 2 s.c. Secukinumab 150 mg PFS injections every 4 weeks
- AIN457 300 mg - Start of Relapse (SoR) (Type: EXPERIMENTAL): Start of relapse: 2 s.c. Secukinumab 150 mg PFS injection every 4 weeks~Otherwise: 2 s.c. PBO Secukinumab PFS injections every 4 weeks
- AIN457 300 mg - Open Label (OL) (Type: EXPERIMENTAL): Open Label - Secukinumab 300mg every 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Cochlear Baha 5 SuperPower Sound Processor on the Baha Attract System

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult subjects ≥ 18 years of age~* Mixed hearing loss in the ear to be implanted. Bone conduction thresholds with pure tone average (PTA4, Mean of 0.5, 1, 2 and 4kHz) of 30-55 dBHL or~* Single-sided sensorineural deafness: Bone conduction thresholds with a pure tone average \[PTA4, Mean of 0.5, 1, 2 and 4 kHz\] of lower or 30 dBHL in the best ear. Subjects who have, for some reason, experienced no or limited benefit from other sound processors when tested on a Baha Softband.~* Subjects suitable for surgery according to the recommended surgical procedure for Cochlear Baha 5 SuperPower with no previous implant on the side to be investigated.~* Signed inform consent.~Exclusion Criteria:~* Subject scheduled for simultaneous bilateral implant surgery. The investigation is limited to subjects with unilateral use of the Investigational device (however, bilateral hearing loss is not an exclusion criterion).~* Suitable implant position for the BI300 Implant (4 mm or 3 mm) not found during surgery due to insufficient bone quality and/or bone thickness~* Less than 3 mm soft tissue thickness at the planned implant site. (Intra-operative exclusion criteria judged by the surgeon at Visit 1 or Visit 2 according to local practice).~* Subjects that have received radiation therapy at the same side of the skull where the Investigational device will be positioned.~* Uncontrolled diabetes as judged by the investigator.~* Condition that could jeopardise osseointegration and/or wound healing (e.g. osteoporosis, psoriasis and long-term systemic use of corticosteroids) or condition that may have an impact on the outcome of the investigation as judged by the investigator.~* Unable to follow investigational procedures, e.g. to complete quality of life scales.~* Participation in another clinical investigation with pharmaceutical and/or device.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Baha 5 SuperPower on Baha Attract System (Type: EXPERIMENTAL): The device involves the following parts:~The sound processor unit, an actuator unit and a cable, the Sound Processor Magnet (SP Magnet) of the Baha Attract System, the BIM400 Baha Implant Magnet that is fixated to the BI300 Implant, a snap coupling.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Formulation and Clinical Evaluation of Ethosomal and Liposomal Preparations of Anthralin in Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients with mild to moderate, stable chronic plaque psoriasis.~Exclusion Criteria:~* patients with severe psoriasis.~* Patients received any topical or systemic treatment for psoriasis one month before the start of the study.

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- ethosomal anthralin (Type: EXPERIMENTAL): Group 1: included 10 psoriatic patients will be treated with ethosomal preparation of anthralin. Patients will be treated with this preparation with short contact (only one hour) daily up to 8 weeks.
- liposomal anthralin (Type: ACTIVE_COMPARATOR): Group 2: included 10 psoriatic patients will be treated with liposomal preparation of anthralin. Patients will be treated with this preparation with short contact (only one hour) daily up to 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria~* Require long-term administration of low-dose aspirin (81 mg/day or 100 mg/day)~* Confirmed to have a history of gastric or duodenal ulcer~Exclusion Criteria~-Confirmed to have acute gastro duodenal mucosal lesions, gastric or duodenal ulcer, or upper gastrointestinal (esophagus, stomach, duodenum) bleeding Confirmed to have reflux esophagitis or long segment Barrett's esophagus

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- E3810 5 mg (Type: EXPERIMENTAL): None
- E3810 10 mg (Type: EXPERIMENTAL): None
- Teprenone 150 mg (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria: moderate to severe AS, prior radiographic evidence according to the Modified NY Criteria (1984), inadequate response to NSAIDs. -- Exclusion criteria: pregnancy or lactation, on-going infectious or malignant process on a chest X-ray or MRI, previous exposure to IL-17 or IL-17R targeting therapies, previous exposure to any biological immunomodulating agent excluding TNF antagonists, previous cell depleting therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Secukinumab 10 mg/kg i.v. / 300 mg s.c. (Type: EXPERIMENTAL): Three i.v. infusions: at Baseline and weeks 2 and 4, followed by one s.c. injection every four weeks until the end of the study.
- Secukinumab 10 mg/kg i.v. / 150 mg s.c. (Type: EXPERIMENTAL): Three i.v. infusions: at Baseline and weeks 2 and 4, followed by one s.c. injection every four weeks until the end of the study.
- Placebo i.v. and s.c. (Type: PLACEBO_COMPARATOR): Three i.v. infusions: at Baseline and weeks 2 and 4, followed by one s.c. injection at weeks 8 and 12. At week 16, patients were re-randomised to one of the active treatment arms, to receive secukinumab s.c. Q4W until the end of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Congestive Heart Failure Weight Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18-85 years old~* Admitted to hospital with a primary diagnosis of heart failure or fluid overload~* Ambulatory with a medical order to be out of bed~* Able to stand on a scale~* Have no problems with balance~Exclusion Criteria:~* Patients with a primary diagnosis other than heart failure or fluid overload~* Patients diagnosed with renal failure~* Non-English speaking~* Unable to follow directions or consent due to cognitive impairment~* Medical order for bed rest~* Involved in another study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Body weight taken in a standing position (Type: EXPERIMENTAL): Subjects will be weighed in the early morning, as standard of care dictates. They will also be weighed after evening medications are given, around 9pm. The evening weight is not standard, therefore considered the study intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, \>=60 years of age;~* CD20+ chronic lymphocytic leukemia (CLL);~* no previous treatment for CLL;~* ECOG performance status 0-1.~Exclusion Criteria:~* co-morbid conditions requiring long term use of systemic corticosteroids during study treatment;~* history of severe cardiac disease;~* transformation to aggressive B-cell malignancy.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Use of Sublingual Tacrolimus in Adult Blood and Marrow Transplant Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Individuals will be identified from within the adult allogeneic BMT program at Mayo Clinic in Rochester, Minnesota~* Adults prescribed tacrolimus for treatment or prevention of Graft Versus Host Disease (GVHD)~Exclusion Criteria:~* Vulnerable populations~* Patients with contraindications to tacrolimus, inclusive of hypersensitivity, history of posterior reversible encephalopathy syndrome or calcineurin-inhibitor induced thrombotic microangiopathy~* Lacking the capacity to consent in English and declining to participate in research

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Allogeneic blood or marrow transplantation (Type: EXPERIMENTAL): Subjects undergoing allogeneic blood or marrow transplantation (BMT) at Mayo Clinic in Rochester Minnesota

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus (T1D)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DEVICE_FEASIBILITY
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
* Participants with T1DM for at least 2 years and who have used an insulin delivery system with any rapid-acting insulin analog for the preceding 6 months~* Have a body mass index of 18.5 to 37 kilogram per meter squared~* Have a hemoglobin A1c level ≥6.0% and ≤9.0%~Exclusion Criteria:~* Have known allergies or history of hypersensitivity to insulin lispro~* Have had an episode of severe hypoglycemia within the past 6 months~* Have had more than 1 episode of diabetic ketoacidosis in the past 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- AID System Containing Insulin Lispro (Type: EXPERIMENTAL): The AID system is comprised of a continuous subcutaneous insulin infusion (CSII) pump component with a hybrid closed-loop control (HCLC) algorithm, and a continuous glucose monitor (CGM) component.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* type 2 diabetes~* BMI 20-45kg/m2 inclusive~Exclusion Criteria:~* females who are pregnant, lactating or within \<6 weeks post-partum~* current symptomatic heart failure (NYHA Class III-IV)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- albiglutide weekly injection (Type: EXPERIMENTAL): albiglutide weekly subcutaneous injection
- insulin glargine (Type: ACTIVE_COMPARATOR): insulin glargine daily injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of a Topical Estradiol Gel for Treatment of Postmenopausal Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal women~* serum estradiol level less than or equal to 20 pg per mL~* serum FSH greater than 40 mIU per mL~Exclusion Criteria:~* Pathological cancer findings on screening~* abnormal endometrium~* serious hepatic, renal or cardiac disease

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of the PRO-174 Versus Sophixín Ofteno®, on the Ocular Surface of Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent.~* Systemically and ophthalmologically healthy subjects evaluated during the clinical history.~* Age between 18 to 45 years.~* Both genders.~* Blood tests (complete blood count, blood chemistry of three elements and liver function tests) within normal parameters specified by the reference laboratory with a lower and upper margin of 10%.~* Vital signs within normal parameters. (Vital signs at rest: blood pressure ≤ 139/89 mmHg, heart rate 60 -100 beats per minute and respiratory rate of 12-24 breaths per minute).~* Visual capacity 20/30 or better, in both eyes.~* Intraocular pressure ≥11 and ≤ 21 mmHg.~Exclusion Criteria:~General criteria~* Subjects with a history of hypersensitivity to any of the components of the research products.~* Subject users of topical ophthalmic medications of any pharmacological group.~* Subject users of medication by any other route of administration.~* Pregnant or lactating women.~* Women of childbearing age, who do not ensure a hormonal contraceptive method or intrauterine device during the study period or without a history of bilateral tubal obstruction, oophorectomy or hysterectomy; as fertile age we understand women who have not had their menopause, defined as 12 months since the last menstruation in women over 40 years.~* Subjects with participation in clinical research studies 90 days prior to inclusion in the present study.~* Diagnosis of liver disease or elevation to three times the normal upper value of any of the following liver enzymes: aspartate transferase (AST), alanine transferase (ALT) or bilirubin.~* Inability to attend or answer the evaluations made in each of the visits.~* Positive smoking (specified as cigarette consumption regardless of amount and frequency)~* Positive alcoholism (specified as the consumption of alcoholic beverages, regardless of quantity and frequency, during the study intervention period).~* Contact lens users.~* An occlusive iridocorneal angle, defined as a trabecular mesh visible at less than 90 ° from the angular circumference to gonioscopy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- PRO-174 (Type: EXPERIMENTAL): Active ingredient: Levofloxacin 0.5%~o Dosage: 1 drop in both eyes, 8 times a day during the waking period
- Sophixín Ofteno® (Type: ACTIVE_COMPARATOR): o Dosage: 1 drop in both eyes, 8 times a day during the waking period

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recurrent or Progressive Glioma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed malignant recurrent glioma\*, including any of the following:~  * Glioblastoma~    * Glioblastoma multiforme~* Recurrent disease or progressive primary disease~* Surgically accessible tumor for which surgical resection is indicated and has not been previously irradiated~* Prior radiotherapy required~* No prior oncophage therapy or immunotherapy for glioma~PATIENT CHARACTERISTICS:~* Karnofsky performance status 80-100%~* Life expectancy ≥ 8 weeks~* Absolute granulocyte count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Alkaline phosphatase and serum glutamic-pyruvic transaminase (SGPT) \<=2.5 times normal~* Bilirubin \< 1.5 mg/dL~* Blood Urea Nitrogen (BUN) \< 1.5 times normal OR creatinine \< 1.5 times normal~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective barrier contraception during and for at least 4 weeks after completion of study treatment~* No uncontrolled active infection~* No bleeding diathesis~* No psychiatric or medical situation that would preclude study compliance~* No unstable or severe concurrent medical condition~* No other cancer or concurrent malignancy within the past 5 years except adequately treated nonmetastatic in situ carcinoma of the uterine cervix, nonmetastatic nonmelanoma skin cancer, or in complete remission and off all therapy for that disease~* No systemic autoimmune disease (e.g., Hashimoto's thyroiditis) and/or any history of primary or secondary immunodeficiency~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* At least 2 weeks since prior vincristine~* At least 6 weeks since prior nitrosoureas~* At least 4 weeks since prior temozolomide or other cytotoxic chemotherapy~* At least 4 weeks since prior investigational agents~* At least 1 week since prior noncytotoxic agents~* At least 3 weeks since prior procarbazine~* No radiotherapy within the past 4 weeks

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase 1: Vaccine (Type: EXPERIMENTAL): Patients received 25 micrograms of HSPPC-96 bi-weekly or weekly for the first 4 vaccinations followed by biweekly injections.
- Phase 2: Vaccine (Type: EXPERIMENTAL): Treatment consisted of 25 mcg of HSPPC-96 weekly for at least 4 weeks, followed by biweekly injections (pending vaccine availability) for up to 52 weeks from the date of surgical resection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete